Prestige Consumer Healthcare (PBH) Capital Leases (2019 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Capital Leases came in at $18.7 million in Q4 2025, up 357.49% year-on-year from $4.1 million in Q4 2024, and down 3.45% quarter-over-quarter from $19.3 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Capital Leases (2019 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Capital Leases history runs 7 years deep, the most recent figure standing at $18.7 million for Q4 2025.
- On a quarterly basis, Capital Leases rose 357.49% year-over-year to $18.7 million in Q4 2025; TTM through Dec 2025 was $18.7 million, a 357.49% increase from a year earlier, with the FY2025 full-year figure at $20.6 million, up 11890.7% from the prior year.
- Capital Leases retreated to $18.7 million in Q4 2025 per PBH's latest filing, from $19.3 million in the prior quarter.
- Across five years, Capital Leases topped out at $20.6 million in Q1 2025 and bottomed at $126000.0 in Q3 2024.
- The 5-year median for Capital Leases is $3.9 million (2022), against an average of $6.2 million.
- Across the five-year window, Capital Leases tumbled 92.95% in 2023 and jumped 15232.54% in 2025, its largest moves.
- Year by year, Capital Leases stood at $4.8 million in 2021, then slumped by 50.61% to $2.4 million in 2022, then sank by 91.82% to $195000.0 in 2023, then soared by 1990.77% to $4.1 million in 2024, then surged by 357.49% to $18.7 million in 2025.
- Per Business Quant, the three latest PBH Capital Leases figures stand at $18.7 million (Q4 2025), $19.3 million (Q3 2025), and $20.0 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.65 Mn |
| Sep 30, 2025 | 19.32 Mn |
| Jun 30, 2025 | 19.98 Mn |
| Mar 31, 2025 | 20.62 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Sep 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 149,000.00 |
| Mar 31, 2024 | 172,000.00 |
| Dec 31, 2023 | 195,000.00 |
| Sep 30, 2023 | 218,000.00 |
| Jun 30, 2023 | 945,000.00 |
| Mar 31, 2023 | 1.67 Mn |
| Dec 31, 2022 | 2.38 Mn |
| Sep 30, 2022 | 3.09 Mn |
| Jun 30, 2022 | 3.80 Mn |
| Mar 31, 2022 | 4.50 Mn |
| Dec 31, 2021 | 4.83 Mn |
| Sep 30, 2021 | 5.49 Mn |
| Jun 30, 2021 | 6.16 Mn |
| Mar 31, 2021 | 6.82 Mn |